A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Conditions
Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
St Vincent's Hospital, Sydney, New South Wales, Australia
Contact: Study coordinator (Hao-Wen Sim, MD)Integrated Clinical Oncology Network (ICON) Pty Ltd, Woolloongabba, Queensland, Australia
Contact: Study coordinator (Vladimir Andelkovic, MD)The Alfred Hospital, Melbourne, Victoria, Australia
Contact: Study coordinator (Stuart Roberts, MD)Linear Clinical Research, Murdoch, Western Australia, Australia
Contact: Study coordinator (Tim Humphries, MD)Pusan National Univesity Hospital, Busan, South Korea
Contact: Study coordinator (Jeong Heo, MD)Cha University Bundang Medical Center, Gyeonggi-do, South Korea
Contact: Study coordinator (Hongjae Jeoon, MD)Seoul National University Hospital, Seoul, South Korea
Contact: Study coordinator (Yoon Jun Kim, MD)National Taiwan University Hospital, Taipei, Taiwan
Contact: Study coordinator (Chih-hung Hsu)Taipei Tzu Chi Hospital, Taipei, Taiwan
Contact: Study coordinator (Her-shyong Shiah)
Study leads
Matthew Maurer, MD
Study Director
Myeloid Therapeutics